# Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

> **NCT07024706** · PHASE2 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07024706
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-05-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024706, "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07024706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*